Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients

9 May 2013

Abstract excerpt

Despite the growing understanding of the mechanisms of carcinogenesis, cancers of the central nervous system are usually associated with unfavorable prognosis. The use of an appropriate molecular marker may improve the treatment outcome by allowing early diagnosis and treatment susceptibility monitoring. Since methylation of tumor-derived DNA can be detected in the serum of cancer patients, this makes DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23661397
DOI: 10.1007/s13353-013-0149-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patientsPMID 23661397Read ↗

p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas.Semantic proximity Read ↗

DNA methylation analysis with methylation‐sensitive high‐resolution melting (MS‐HRM) reveals gene panel for glioma characteristicsSemantic proximity Read ↗

Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various gradesSemantic proximity Read ↗

MGMT-Methylation in Non-Neoplastic Diseases of the Central Nervous SystemSemantic proximity Read ↗

CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours.Semantic proximity Read ↗

Promoter Hypermethylation of the DNA Repair Gene O 6 ‐ Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse AstrocytomasSemantic proximity Read ↗

Epigenetic silencing of multiple genes in primary CNS lymphomaSemantic proximity Read ↗

Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.Semantic proximity Read ↗

CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patientsSemantic proximity Read ↗

Global DNA demethylation as an epigenetic marker of human brain metastasesSemantic proximity Read ↗

High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.Semantic proximity Read ↗

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.